At the crossroads of resistance and hope, Akeso presented data in April 2026 suggesting that a three-drug combination anchored by cadonilimab can meaningfully slow the advance of lung cancer in patients for whom standard immunotherapy has already failed. For those with advanced non-small cell lung cancer who have reached what medicine often treats as a dead end, a seven-month pause in disease progression and a 95.2 percent disease control rate represent something rarer than statistics — they represent time. The findings, shared at the European Lung Cancer Congress, extend the story of the worl
The Manila Times
· Apr 07, 2026
· health
· 4 min read
High
Sourcing: Characterized
Akeso's Cadonilimab Shows Promise in Immunotherapy-Resistant Lung Cancer
Patients with advanced metastatic lung cancer who have failed prior immunotherapy treatments represent a population with limited treatment options and poor prognosis.
◉
Health & Medicine
8098 related articles
Moderna's personalized mRNA melanoma vaccine shows promise in preventi…
CBS News · 100% match
Blood test could predict Covid-19 mortality risk, study finds
BreakingNews.ie · 99% match
Hadassah performs world's first alpha radiation treatment for recurren…
jpost.com · 99% match
Dr. Reddy's Wins Semaglutide Approval as Novo Nordisk Patent Challenge…
NDTV Profit · 99% match
EU safety committee reviews reports of menstrual changes after mRNA CO…
CNBC · 99% match
Related Coverage
The Guardian · Aug 20
Hundreds of thousands await GCSE results as gender gap narrows to 10-year low
Hundreds of thousands of UK students received GCSE results showing overall grade improvements in 2025, with the gender g…
The Straits Times · Aug 20 Ebola spreads beyond Congo epicentre, overwhelming treatment capacityEbola cases in DRC are accelerating outside the initial Ituri epicenter, with North Kivu and Haut-Uélé provinces experie…
Science Daily · Aug 20 1,000+ genetic switches explain why women face higher autoimmune disease riskResearchers identified over 1,000 genetic switches that function differently in male and female immune cells, explaining…
News-Medical · Aug 20 Brain's Local Wiring May Buffer Cognitive Decline in Older AdultsUSC researchers found that white matter integrity helps protect cognitive function in older adults by compensating for g…
Bias & Framing
⚖
Article presents pharmaceutical company's clinical trial results with promotional language and lacks independent medical expert perspective or critical analysis of limitations.
Bias Direction
center-right
Confidence
HIGH
Press release republication with promotional framing emphasizing positive outcomes while minimizing discussion of limitations, side effects, or comparative efficacy data.
world's first approved bispecific antibody
clinically meaningful benefit
significant unmet medical need
broad recognition from physicians and patients
robust evidence
highly preferable backbone
difficult-to-treat population
durable disease control
Independent oncologist commentary on clinical significance
Comparative efficacy data versus existing second-line treatments
Detailed adverse event profiles and frequency rates
Patient accessibility and cost considerations
Regulatory or medical society perspectives on approval pathway
Limitations of single-arm study design
Long-term survival data (only PFS reported)
Geopolitical Impact
🌎
Chinese biotech Akeso's immunotherapy drug shows clinical promise, strengthening China's position in global oncology markets and reducing dependence on Western pharmaceutical dominance.
Escalation Risk
low
Confidence
MED
China
Europe
Asia-Pacific
Global pharmaceutical markets
China advances its biotech capabilities and pharmaceutical soft power through innovative cancer treatments. Akeso's Hong Kong listing and European clinical validation signal China's growing influence in high-value healthcare innovation, potentially shifting treatment paradigms away from Western-dominated immunotherapy approaches.
Similar to China's rise in generic pharmaceuticals in the 2000s, but now competing in premium innovation sectors, paralleling India's software industry ascendancy through quality and cost advantages.
Economic Lens
📈
Akeso's cadonilimab immunotherapy shows strong efficacy in treatment-resistant lung cancer, potentially expanding market opportunities in oncology and supporting pharmaceutical sector growth.
Market Signal
bullish
Confidence
HIGH
Pharmaceutical and Biotechnology
Healthcare and Medical Devices
Hospital and Clinical Services
Medical Research and Development
Patients with immunotherapy-resistant lung cancer gain access to a potentially more effective treatment option with manageable side effects, improving survival outcomes and quality of life for this difficult-to-treat population.
Regulatory bodies may expedite approval pathways for combination therapies addressing unmet medical needs. Healthcare systems may need to evaluate reimbursement strategies for bispecific antibody combinations. Pricing policies may emerge as these advanced therapies enter broader clinical use.